Separately, ValuEngine raised shares of Acura Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, December 1st.
Shares of Acura Pharmaceuticals (OTCMKTS ACUR) opened at $0.70 on Wednesday. Acura Pharmaceuticals has a 52-week low of $0.29 and a 52-week high of $1.40. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.23 and a current ratio of 1.23.
In other Acura Pharmaceuticals news, Director Bruce F. Wesson bought 335,734 shares of the stock in a transaction on Thursday, December 14th. The stock was purchased at an average price of $0.10 per share, with a total value of $33,573.40. Following the completion of the purchase, the director now owns 394,404 shares in the company, valued at $39,440.40. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Claudius Llc sold 2,195,734 shares of the business’s stock in a transaction dated Friday, December 14th. The stock was sold at an average price of $0.10, for a total value of $219,573.40. The disclosure for this sale can be found here. Insiders have purchased 1,035,734 shares of company stock valued at $103,573 in the last ninety days. 5.60% of the stock is currently owned by company insiders.
WARNING: This report was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3147013/acura-pharmaceuticals-acur-pt-lowered-to-0-58-at-sp-equity-research.html.
About Acura Pharmaceuticals
Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.
Receive News & Ratings for Acura Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.